Brachytherapy

Papers
(The median citation count of Brachytherapy is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
PPP03 Presentation Time: 10:48 AM34
BP02 Presentation Time: 4:09 PM33
Thursday, July 11, 20249:00 AM - 10:00 AMGPP01 Presentation Time: 9:00 AM23
Thursday, July 11, 20244:00 PM - 5:00 PM MPP01 Presentation Time: 4:00 PM20
PHSOR06 Presentation Time: 9:25 AM19
PO024918
BP08 Presentation Time: 5:03 PM15
PO042515
PPP02 Presentation Time: 10:39 AM15
PO032415
MPP02 Presentation Time: 4:09 PM15
PO041714
PO022714
Evaluation of variability in applicator position and organs at risk dose in fractionated intracavitary brachytherapy for cervical cancer13
A new way to visualize prostate brachytherapy needles using ultrasound color Doppler and needle surface modifications12
Clinical outcomes of adaptive intracavitary and interstitial brachytherapy technique in locally advanced cervical cancer: A real-world data12
Biochemical outcome of prostate cancer patients treated with hypofractionated external radiation and a single high-dose-rate brachytherapy boost11
GPP03  Presentation Time: 9:33 AM11
P010511
PHSOP2  Presentation Time: 9:05 AM11
PO4710
PSOR12  Presentation Time: 5:25 PM10
PO3510
PO9310
Editorial Board10
PSOR03  Presentation Time: 12:10 PM9
After ASCENDE-RT: Biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a po9
Editorial Board9
Factors associated with late local failure and its influence on survival in men undergoing prostate brachytherapy9
PSOR8  Presentation Time: 12:05 PM9
3D-printed radiopaque episcleral plaques with radioactive collimating cavities for enhanced dose delivery in brachytherapy9
PL02 Presentation Time: 1:45 PM8
Association between rectal spacer use and bowel, urinary, and sexual dysfunction following prostate cancer brachytherapy: U.S. claims data analysis8
PO02348
PO04218
HDR and PDR brachytherapy for facial nonmelanoma skin cancer: Outcome and toxicity assessment for 155 patients8
MSOR11 Presentation Time: 8:50 AM8
Effects of pain management using nonsteroidal anti-inflammatory drug suppositories during brachytherapy for cervical cancer: A single-center prospective observational study8
Impact of MRI-based planning in transperineal interstitial brachytherapy for locally advanced cervix tumors: Clinical, dosimetric and toxicity outcomes8
P03017
MSOR12 Presentation Time: 8:55 AM7
PP05  Presentation Time: 5:06 PM7
Masthead7
Author Index7
PPP04  Presentation Time: 10:57 AM7
Exclusive Ru-106 brachytherapy for the management of a recurrent corneo: Conjunctival squamous cell carcinoma7
PSOR02  Presentation Time: 4:35 PM7
PRPP05  Presentation Time: 11:06 AM7
Determination of the optimal time for planning SAVI brachytherapy for APBI7
American Brachytherapy Society (ABS) rectoprostatic gel spacer consensus statement7
PL02  Presentation Time: 1:45 PM7
Sunday, June 19, 202211:30 AM - 12:30 PMGSOR13  Presentation Time: 11:30 AM6
PO46  Presentation Time: 4:45 PM6
Masthead6
High-dose-rate brachytherapy for airway malignancy a single institution experience6
Radical trachelectomy and adjuvant vaginal brachytherapy to preserve fertility in pediatric cervical adenocarcinoma6
PP02  Presentation Time: 9:10 AM6
Table of Contents6
PO216
GSOR14  Presentation Time: 11:35 AM6
Novel portable apparatus for outpatient high-dose-rate (HDR) brachytherapy in penile cancer6
PHSOR05  Presentation Time: 12:50 PM6
PO106
Comparison of novel shielded nasopharynx applicator designs for intracavitary brachytherapy6
PO206
Table of Contents6
The case for risk-stratified IORT for early breast cancer6
PHSOR04  Presentation Time: 12:45 PM6
Quantifying geometric and dosimetric advantage from the use of rectal spacing in HDR prostate brachytherapy5
PO1145
Cs-131 prostate brachytherapy boost and effect of hydrogel rectal spacer on long-term patient-reported rectal bleeding and bowel quality of life5
Increasing global access to brachytherapy: The ABS 300 in 10 initiative and ongoing international efforts5
Skin Posters PO07015
PO01195
MSOP03  Presentation Time: 8:10 AM5
PO02415
GSOR04  Presentation Time: 12:15 PM5
Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up5
Is hemi-gland focal LDR brachytherapy as effective as whole-gland treatment for unilateral prostate cancer?5
PSOR02 Presentation Time: 11:35 AM5
PO01095
GPP06  Presentation Time: 11:15 AM5
GSOR13  Presentation Time: 12:30 PM5
Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review5
Partial breast irradiation: An updated consensus statement from the American brachytherapy society5
I-125 eye-plaque seed economics: To re-use or to not re-use? A single institutional cost savings analysis of re-using I-125 radioactive seeds for eye—Plaque brachytherapy5
MSPP03  Presentation Time: 4:20 PM5
PO04245
PO02425
MPP02  Presentation Time: 4:09 PM5
MSOP06  Presentation Time: 8:25 AM5
Targeting the GTV in medically inoperable endometrial cancer using brachytherapy4
The association of vagina equivalent dose in 2Gy fraction (EQD2) to late vagina toxicity in patients of cervical cancer treated with WPRT plus IGABT4
US-guided EM tracked system for HDR brachytherapy: A first in-men randomized study for whole prostate treatment4
Randomized trial comparing hypnosis versus standard management on patient anxiety and pain during pelvic brachytherapy applicator removal4
PO914
Comment on “How accurate is applicator reconstruction in HDR gynecological brachytherapy? Patient-specific results from an electromagnetic tracking system designed to intercept errors before radiation4
PO194
The American Brachytherapy Society and Indian Brachytherapy Society consensus statement for the establishment of high-dose-rate brachytherapy programs for gynecological malignancies in low- and middle4
Comment on “high-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy for localized prostate cancer: An evidence-based consensus statement”4
On the value of an EM tracking quality assurance system for pretreatment verification of needle digitization accuracy in ultrasound-based prostate HDR brachytherapy4
A primer on time-driven activity-based costing in brachytherapy4
PO154
Improving efficiency and reducing costs of MRI-Guided prostate brachytherapy using Time-Driven Activity-Based costing4
US-guided versus US-assisted tandem insertion for cervical cancer: A nomenclature proposal4
The NorCal brachytherapy waste audit: A simple, validated, toolkit for clinician led waste reduction4
Is single implant and multiple fractions radio-biologically iso-effective for cervical cancer high-dose-rate brachytherapy: Observation from patient cohorts during COVID pandemic4
Development of a dosimetric phantom using OSLDs or TLD-100 for external audits of high-dose-rate 192Ir brachytherapy sources: Preliminary results4
PP02  Presentation Time: 10:09 AM4
Thursday, June 22, 20233:30 PM - 4:30 PMPP01  Presentation Time: 3:30 PM4
PHSOR06  Presentation Time: 12:55 PM4
Toward 3D-TRUS image-guided interstitial brachytherapy for cervical cancer4
GSOR09 Presentation Time: 12:10 PM3
PSOR3  Presentation Time: 11:40 AM3
PSOR7  Presentation Time: 12:00 PM3
Dosimetric characterization and experimental validation for a low-kV FPXS electronic brachytherapy system3
Development of a phantom and analysis of brachytherapy dosimetry using the sulfamic acid/electron paramagnetic resonance system3
PO863
Rule-based AI automated adaptive treatment planning for image guided cervical cancer brachytherapy3
PO40  Presentation Time: 4:45 PM3
PRSOP03  Presentation Time: 11:40 AM3
PO533
PRSOP08  Presentation Time: 12:05 PM3
PPP05 Presentation Time: 11:06 AM3
PO03203
PO01103
Author Index of the Abstracts of the 2022 American Brachytherapy Society Annual Meeting3
MSOR9 Presentation Time: 5:40 PM3
A novel dose-based intra-preplan method for high-dose-rate brachytherapy in cervical cancer using modeling and optimization algorithms3
Four-fraction ultra-accelerated minimal breast irradiation in early breast cancer: The initial feasibility results of an institutional experience3
P03043
PP05  Presentation Time: 11:36 AM3
Intra-operative process efficiency for in-room MRI-guided combined intracavitary/interstitial brachytherapy for cervical cancer3
PO33  Presentation Time: 10:30 AM3
PRPP02  Presentation Time: 10:39 AM3
PP04  Presentation Time: 9:47 AM3
PO02613
MSOR11 Presentation Time: 5:50 PM3
Are outcomes of locally advanced cervical cancer associated with prebrachytherapy hemoglobin values and transfusion practice? An observational study comparing two large academic centres with divergent3
Targeting prostate lesions on multiparametric MRI with HDR brachytherapy: Optimal planning margins determined using whole-mount digital histology3
Dosimetric evaluation of iodine-125 brachytherapy for brain tumors using MR guidance combined with a three-dimensional non co-planar template3
A general framework to develop a radiomic fingerprint for progression-free survival in cervical cancer3
Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer3
Intraoperative radiation and electronic brachytherapy in Brachytherapy: A look back and forward3
The influence of time and implants in high-dose rate image-guided adaptive brachytherapy for locally advanced cervical cancer3
PO523
Wound complications and local recurrence do not differ when using interstitial brachytherapy versus external beam radiation therapy for soft tissue sarcoma3
Laminaria tent insertion in preplanning MRI for CT-based cervical cancer brachytherapy3
GPP04  Presentation Time: 9:42 AM3
PO02203
Thursday, July 11, 20244:00 PM - 5:30 PM BP01 Presentation Time: 4:00 PM3
PO03142
Feasibility of balloon rectal spacer implantation in HDR and LDR brachytherapy for prostate cancer treatment2
Definitive treatment for primary urethral cancer: A single institution's experience with organ-preserving brachytherapy2
PO03112
GSOR06  Presentation Time: 11:55 AM2
Uncertainty in magnetic resonance imaging-based prostate postimplant dosimetry: Results of a 10-person human observer study, and comparisons with automatic postimplant dosimetry2
PO492
Systematic review of brachytherapy for symptom palliation2
Comparing long-term sexual dysfunction across different uterine cancer treatment modalities2
MSPP05  Presentation Time: 4:40 PM2
PL03 Presentation Time: 2:00 PM2
EM tracking with conventional CT tables: Quantifying and correcting for electromagnetic field distortion2
PP04  Presentation Time: 11:27 AM2
Saturday, July 13, 202410:30 AM - 11:30 AM GPP01 Presentation Time: 10:30 AM2
GYN Posters PO012
Patient-specific cylinder templates for hybrid interstitial vaginal brachytherapy: Feasibility of automated 3-D design, 3D printing, and dosimetric outlook2
PHSOP6  Presentation Time: 9:25 AM2
PO02582
A first-in-human randomized clinical trial of graphics processing units based multi-criteria optimization (gMCO) versus IPSA in high-dose-rate prostate brachytherapy2
How do you do it?: Gynecologic brachytherapy best practices at high volume institutions within the United States and Canada2
PO04282
Dosimetric evaluation of a novel modular cell irradiation platform for multi-modality in vitro studies including high dose rate brachytherapy2
Surgically targeted radiation therapy versus stereotactic radiation therapy: A dosimetric comparison for brain metastasis resection cavities2
Clinical and dosimetric outcomes of a 3-fraction high-dose-rate brachytherapy boost for the treatment of locally advanced cervical cancer in a safety net hospital2
Prospective validation of a machine learning model for applicator and hybrid interstitial needle selection in high-dose-rate (HDR) cervical brachytherapy2
Sigmoid dose accumulation and reporting for multifractionated brachytherapy for cervical cancer: Methodological development of sigmoid points through virtual endoscopic method2
PPP03  Presentation Time: 10:48 AM2
PO02332
PO322
PO01112
Table of Contents2
Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer2
MSOR7 Presentation Time: 5:30 PM2
Table of Contents2
PO122
Actinium-225 Targeted Agents: Where Are We Now?2
MPP05  Presentation Time: 4:36 PM2
Gastrointestinal and genitourinary toxicity following high dose rate vaginal cuff brachytherapy for endometrial cancer2
What is appropriate target delineation for MRI-based brachytherapy for medically inoperable endometrial cancer?2
Role of the gel spacer in safely delivering whole pelvic radiation therapy without central shielding in computed tomography-based image-guided adaptive brachytherapy for uterine cervical cancer patien2
PO03102
Masthead2
GSOR06 Presentation Time: 5:25 PM2
GSOR10 Presentation Time: 12:15 PM2
P01142
Combined operative and radiotherapeutic treatment for locally recurrent gynaecologic cancer with pelvic wall invasion: A monocentric retrospective study2
PHSOR08  Presentation Time: 1:05 PM2
GSOR02  Presentation Time: 11:35 AM2
Long-term oncologic outcomes of high-dose-rate interstitial brachytherapy (interventional radiotherapy) in oral tongue squamous cell carcinoma; 15 years of experience from a tertiary cancer center2
PO27  Presentation Time: 7:40 AM2
GSOR12 Presentation Time: 5:55 PM2
PO102
MSS11  Presentation Time: 4:35 PM2
PO02292
Masthead2
PP02  Presentation Time: 8:29 AM2
PO04082
Table of Contents2
Brachytherapy for rectal and anal cancer: Where are we and current perspectives?2
Improving plan quality in cervical brachytherapy using a simple knowledge-based prediction tool for OAR dose (D2cm3)2
Haralick texture feature analysis for Monte Carlo dose distributions of permanent implant prostate brachytherapy2
PSA: Declining utilization of prostate brachytherapy2
Friday, June 17, 20222:30 PM - 3:30 PM PHSPP01  Presentation Time: 2:30 PM1
Saturday, July 13, 202411:30 AM - 12:30 PMPSOR01 Presentation Time: 11:30 AM1
MSS04  Presentation Time: 4:00 PM1
PO02631
PO131
Primary vaginal cancer treated with high-dose rate brachytherapy and intraprocedural magnetic resonance imaging1
PO01021
PO051
Saturday, July 13, 20249:00 AM - 10:00 AMPHSOR01 Presentation Time: 9:00 AM1
PP04 Presentation Time: 4:27 PM1
Comparing dosimetry of locally advanced cervical cancer patients treated with 3 versus 4 fractions of MRI-guided brachytherapy1
PO1191
PO171
Long-term disease-free survival following salvage brachytherapy for recurrent pediatric rhabdomyosarcoma: Two case reports and review of relevant literature1
PO03091
Long-term oncologic outcomes of low dose-rate brachytherapy compared to hypofractionated external beam radiotherapy for intermediate -risk prostate cancer1
Prostate Posters PO04011
Sunday, June 19, 2022 10:30 AM - 11:30 AMPP07  Presentation Time: 10:30 AM1
Novel use of 3D printing for preoperative dose estimation in the first case of GammaTile spine implantation1
GSOR05  Presentation Time: 12:20 PM1
MSOR7  Presentation Time: 5:15 PM1
GSOR08 Presentation Time: 5:35 PM1
PSOR12 Presentation Time: 12:25 PM1
PO1031
MSOR10 Presentation Time: 8:45 AM1
A feasibility study of utilizing a cadaveric training model for novel robotic bladder cancer brachytherapy techniques1
PO28  Presentation Time: 7:40 AM1
PPP06 Presentation Time: 11:15 AM1
PO1001
From patient to pioneer: The inspiring journey of Dr. Brian Moran1
PO04331
PO02401
GSOR10 Presentation Time: 5:45 PM1
PO01161
Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retr1
Masthead1
Re: Letter to the editor with regards to “Impact of detector selection on commissioning of Leipzig surface applicators with improving immobilization in high-dose-rate brachytherapy” by Li et al.1
0.12949705123901